✦ LIBER ✦

Antibody response in patients with acute nonlymphocytic leukemia

✍ Scribed by Charles A. Schiffer; J. Leonard Lichtenfeld; Peter H. Wiernik; Michael R. Mardiney Jr; J. Mehsen Joseph

Publisher: John Wiley and Sons
Year: 1976
Tongue: English
Weight: 424 KB
Volume: 37
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197605)37:5<2177::aid-cncr2820370504>3.0.co;2-d

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response to 5-azacytidine in patients wi

Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings

✍ Richard A. Larson; Donald L. Sweet; Harvey M. Golomb; Joseph R. Testa; Janet D. 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB 👁 1 views

Exposure histories in acute nonlymphocyt

Exposure histories in acute nonlymphocytic leukemia patients with a prior preleukemic condition

✍ Martin M. Crane; Michael J. Keating 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 385 KB

Acute nonlymphocytic leukemia in a glue

Acute nonlymphocytic leukemia in a glue sniffer

✍ Dr. Michael A. Caligiuri; Amy P. Early; M. J. Marinello; Harvey D. Preisler 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Aryl sulfatase a in acute nonlymphocytic

Aryl sulfatase a in acute nonlymphocytic leukemia

✍ M. V. Pillai; G. W. James III; M. E. King; F. W. Fox; S. C. Choi 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

Meningeal involvement in patients with a

Meningeal involvement in patients with acute nonlymphocytic leukemia incidence, management, and predictive factors

✍ A. W. Dekker; A. Elderson; K. Punt; J. J. Sixma 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 477 KB 👁 2 views

Continuous infusion mitoxantrone in rela

Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia

✍ Lynne S. Kaminer; Kyung E. Choi; Karen M. Daley; Richard A. Larson 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 2 views

Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia. The authors' goal was to treat patients with continuous infusion mitoxantrone in order to maintain cytotoxic steady state levels with acceptable toxicity and to assess the results. Daily mitoxantrone